Quantcast

China NMPA OKs Optune for treatment of certain glioblastoma

Novocure’s Optune has became the first innovative treatment for glioblastoma approved in China in over 15 years, the company said in a Wednesday press release, after it’s global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate.

Read more